Trial Profile

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etrasimod (Primary)
Indications Ulcerative colitis
Focus Adverse reactions
Sponsors Arena Pharmaceuticals

Most Recent Events

17 Oct 2023 Results presented at the 31st United European Gastroenterology Week
27 Oct 2021 Results of post hoc analysis (n=216) assessing the effect of etrasimod on quality of life among participants who participated in Phase 2 trial (OASIS; NCT02447302) and open-label extension (OLE; NCT02536404) trials, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
28 Oct 2020 Results of pooled analysis from OASIS trial and its extension trial presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com